A Phase lll Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral03/06/2014 - 03/05/2017 (PI)
PaxVax, Inc.
A Phase lll Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX020011/01/2013 - 10/31/2016 (PI)
PaxVax, Inc.
A Multicenter, randomized, observer-blinded, active-controlled study evaluating the safety, tolerability pharmacokinetics an efficacy of ceftaroline versus cetriaxone in pediatric subjects with compli01/01/2013 - 06/30/2015 (PI)
Cerexa, Inc.
A multi-center, randomized, observer-blinded, active-controlled study evaluating the safety, tolerability, pharmacokinetics and efficacy of ceftaroline versus cetriaxone plus vancomycin in pediatric10/01/2012 - 09/30/2013 (PI)
Cerexa, Inc.
Long Term Immunity and Safety following Vaccination with the Japanese Ecephalitis Vaccine IC51 in a Pediatric Population in Non-endemic Countries12/12/2011 - 12/11/2012 (PI)
Intercell AG
IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO, JESPECT) IN A PEDIATRIC POPULATION IN NON-ENDEMIC COUNTRIES. UNCONTROLLED, OPEN-LABEL PHASE 3 STUDY02/01/2010 - 06/30/2012 (PI)
Intercell AG
Evaluation of Impact of Antimicrobial Therapy on Carriage of Susceptible and Resistant Streptococcus Pneumoniae09/01/1999 - 06/30/2004 (PI)
SmithKline Beecham
Use of Intrapulmonary Percussive Ventilation to Prevent Respiratory Disease in Adolescents with Impaired Pulmonary Function09/01/1999 - 08/31/2000 (PI)
Deborah Munroe Noonan Memorial Fund Medical Fdn Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF07/06/2021 - 07/06/2024 (PI)
Pfizer, Inc
A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALT03/08/2021 - 03/08/2024 (PI)
Pfizer, Inc
Refugee And Immigrant Health P01/01/1992 - 06/30/2023 (PI)
DPH DHHS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT…06/29/2020 - 06/28/2023 (PI)
Pfizer, Inc
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY…05/29/2020 - 05/28/2023 (PI)
Pfizer, Inc
A Phase 3, Randomized, Double- or Observer-Blinded, Placebo Controlled Trial to Evaluate the…03/09/2020 - 03/09/2023 (PI)
Pfizer, Inc
Clinical Immunization Safety Assessment (CISA) Project - Cli09/29/2016 - 10/28/2022 (PI)
Centers for Disease Control and Prevention/DHHS
ThreeWire BAA/Secondment Agreement10/07/2019 - 10/06/2022 (PI)
ThreeWire Inc.
A PHASE 2b, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY…08/22/2019 - 08/21/2022 (PI)
Pfizer, Inc
CISA COVID09/17/2020 - 03/31/2022 (PI)
CDC
Showing 10 of 15 results.
Show All Results
PXVX-VC-200-00608/24/2017 - 03/15/2021 (PI)
PaxVax, Inc.
CISA Clinical Evaluation Consult Activity09/29/2013 - 10/01/2020 (PI)
CDC
Assessing Feasibility and Impact of Implementing an Oral Water Hydration Strategy to Prevent Post…09/15/2014 - 09/14/2016 (PI)
CDC
A Comparison of a rapid enzyme chromatographic screening test for G6PD deficiency with a quantitativ09/19/2006 - 06/30/2012 (PI)
Binax, Inc Dept of Defense
Boston Area Travel Medicine Network (BATMN)09/30/2007 - 09/29/2011 (PI)
CDC5U19CI000508-03